CStone Finds Tonic in Steady Stream of Drug Approvals, Licensing Deals
Cancer drug specialist reported its first significant revenue in 2020, following a string of milestones capped by a $200 million investment from Pfizer Key takeaways: Strong upfront licensing fees helped…
RELATED ARTICLES
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK -
HBM gets health boost from drug licensing deals
2142.HK
-
Stock disconnect triggers investor exodus from CStone Pharma
2616.HK
-
Everest reaches new heights on growing drug sales
1952.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
Clinical trials come up short again for Alphamab Oncology
9966.HK
-
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK
